I. Helen Torley's most recent trade in Halozyme Therapeutics Inc. was a trade of 20,000 Common Stock done at an average price of $8.1 . Disclosure was reported to the exchange on Sept. 2, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 156,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 136,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Sep 2025 | 20,000 | 176,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 02 Sep 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.70 per share. | 02 Sep 2025 | 16,288 | 737,131 (0%) | 0% | 73.7 | 1,200,393 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.63 per share. | 02 Sep 2025 | 10,500 | 733,719 (0%) | 0% | 74.6 | 783,636 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 73.54 per share. | 02 Sep 2025 | 9,900 | 743,819 (0%) | 0% | 73.5 | 728,006 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.22 per share. | 02 Sep 2025 | 9,500 | 744,219 (0%) | 0% | 74.2 | 705,090 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.33 per share. | 02 Sep 2025 | 7,800 | 736,019 (0%) | 0% | 74.3 | 579,751 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 74.15 per share. | 02 Sep 2025 | 3,412 | 733,719 (0%) | 0% | 74.1 | 252,990 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 75.22 per share. | 02 Sep 2025 | 2,300 | 733,719 (0%) | 0% | 75.2 | 173,015 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 72.49 per share. | 02 Sep 2025 | 300 | 753,419 (0%) | 0% | 72.5 | 21,746 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 196,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 216,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Aug 2025 | 20,000 | 236,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 11 Aug 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.01 per share. | 11 Aug 2025 | 18,717 | 735,002 (0%) | 0% | 63.0 | 1,179,321 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.14 per share. | 11 Aug 2025 | 14,948 | 738,771 (0%) | 0% | 64.1 | 958,839 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.24 per share. | 11 Aug 2025 | 13,042 | 740,677 (0%) | 0% | 63.2 | 824,802 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.00 per share. | 11 Aug 2025 | 6,958 | 733,719 (0%) | 0% | 64.0 | 445,319 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 64.83 per share. | 11 Aug 2025 | 5,052 | 733,719 (0%) | 0% | 64.8 | 327,511 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 63.60 per share. | 11 Aug 2025 | 1,283 | 733,719 (0%) | 0% | 63.6 | 81,596 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 256,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 276,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Jul 2025 | 20,000 | 296,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 08 Jul 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.43 per share. | 08 Jul 2025 | 19,792 | 733,927 (0%) | 0% | 56.4 | 1,116,783 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 55.74 per share. | 08 Jul 2025 | 16,402 | 733,719 (0%) | 0% | 55.7 | 914,215 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.62 per share. | 08 Jul 2025 | 15,746 | 733,719 (0%) | 0% | 57.6 | 907,237 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.74 per share. | 08 Jul 2025 | 4,254 | 749,465 (0%) | 0% | 56.7 | 241,380 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 54.48 per share. | 08 Jul 2025 | 3,598 | 750,121 (0%) | 0% | 54.5 | 196,030 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 57.08 per share. | 08 Jul 2025 | 208 | 733,719 (0%) | 0% | 57.1 | 11,872 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 316,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 336,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2025 | 20,000 | 356,569 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 52.57 per share. | 20 Jun 2025 | 20,000 | 733,719 (0%) | 0% | 52.6 | 1,051,460 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 8.11 per share. | 20 Jun 2025 | 20,000 | 753,719 (0%) | 0% | 8.1 | 162,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 52.96 per share. | 20 Jun 2025 | 20,000 | 733,719 (0%) | 0% | 53.0 | 1,059,200 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.91 per share. | 20 Jun 2025 | 15,511 | 733,719 (0%) | 0% | 53.9 | 836,214 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.11 per share. | 20 Jun 2025 | 4,489 | 749,230 (0%) | 0% | 53.1 | 238,406 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 22,436 | 67,308 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 23 Feb 2025 | 22,436 | 745,800 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 57.75 per share. | 23 Feb 2025 | 12,081 | 733,719 (0%) | 0% | 57.8 | 697,678 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 71,038 | 71,038 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Feb 2025 | 67,027 | 67,027 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 71,810 | 0 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 71,810 | 744,548 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 38,668 | 705,880 (0%) | 0% | 58.3 | 2,253,958 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 21,009 | 21,009 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 21,009 | 726,889 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,875 | 33,749 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 16,875 | 732,451 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,092 | 0 | - | - | Restricted Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 15 Feb 2025 | 13,092 | 679,836 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 11,313 | 715,576 (0%) | 0% | 58.3 | 659,435 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 9,087 | 723,364 (0%) | 0% | 58.3 | 529,681 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 58.29 per share. | 15 Feb 2025 | 7,098 | 672,738 (0%) | 0% | 58.3 | 413,742 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 96,155 | 96,155 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 24,957 | 71,810 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 23,260 | 23,260 | - | - | Performance Stock Unit | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Feb 2025 | 20,008 | 31,364 | - | - | Performance Stock Units | |
| Halozyme Therapeutics Inc | I. Torley Helen | Director, PRESIDENT AND CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 29 Nov 2024 | 10,000 | 666,744 (0%) | 0% | 0 | Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 08 Oct 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 10,000 | 0 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Oct 2024 | 10,000 | 10,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 08 Oct 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.94 per share. | 08 Oct 2024 | 9,100 | 677,644 (0%) | 0% | 53.9 | 490,845 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 51.85 per share. | 08 Oct 2024 | 5,981 | 680,763 (0%) | 0% | 51.8 | 310,097 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.91 per share. | 08 Oct 2024 | 2,404 | 676,744 (0%) | 0% | 53.9 | 129,590 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 53.31 per share. | 08 Oct 2024 | 1,615 | 679,148 (0%) | 0% | 53.3 | 86,096 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 54.57 per share. | 08 Oct 2024 | 900 | 676,744 (0%) | 0% | 54.6 | 49,116 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 24 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2024 | 10,000 | 20,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2024 | 10,000 | 30,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Sep 2024 | 10,000 | 40,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.10 per share. | 24 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 56.1 | 560,970 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 24 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 56.34 per share. | 24 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 56.3 | 563,370 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 24 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 58.21 per share. | 24 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 58.2 | 582,100 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 10 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 59.20 per share. | 10 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 59.2 | 592,030 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,000 | 60,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 10 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,000 | 50,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Sep 2024 | 10,000 | 70,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 59.09 per share. | 10 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 59.1 | 590,870 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 10 Sep 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Sale of securities on an exchange or to another person at price $ 59.09 per share. | 10 Sep 2024 | 10,000 | 676,744 (0%) | 0% | 59.1 | 590,890 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.87 per share. | 13 Aug 2024 | 10,000 | 686,744 (0%) | 0% | 13.9 | 138,700 | Common Stock |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 10,000 | 80,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 10,000 | 90,000 | - | - | Option to Purchase Common Stock | |
| Halozyme Therapeutics Inc | Helen I. Torley | Director, PRESIDENT AND CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Aug 2024 | 10,000 | 100,000 | - | - | Option to Purchase Common Stock |